We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+3.38%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$169M
Cap. Flow
-$159M
Cap. Flow %
-41.28%
Top 10 Hldgs %
88.77%
Holding
17
New
–
Increased
10
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$19.7M
2
QURE icon
uniQure
QURE
+$6.77M
3
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$4.22M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$3.31M
5
BPMC
Blueprint Medicines
BPMC
+$2.34M

Top Sells

Rank Stock Value
1
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$16.1M
2
PVLA
Palvella Therapeutics
PVLA
+$1.31M

Sector Composition

Rank Sector Weight
1 Healthcare 82.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$67.7M 17.58%
1,813,392
+108,000
+6% +$3.31M
SPRO icon
2
Spero Therapeutics
SPRO
$73M
$53.5M 13.89%
3,829,209
– –
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$39.5M 10.25%
448,512
+25,500
+6% +$2.34M
ARWR icon
4
Arrowhead Research
ARWR
$12.4B
$35.9M 9.32%
432,926
+25,000
+6% +$1.86M
QURE icon
5
uniQure
QURE
$3.22B
$35.7M 9.26%
1,157,513
+202,089
+21% +$6.77M
DNTH icon
6
Dianthus Therapeutics
DNTH
$6.09B
$26.3M 6.83%
167,949
+11,561
+7% +$2.12M
NGM
7
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$23.6M 6.12%
1,194,237
+70,000
+6% +$1.64M
RGNX icon
8
Regenxbio
RGNX
$708M
$23.1M 6.01%
595,444
+36,000
+6% +$1.29M
FDMT icon
9
4D Molecular Therapeutics
FDMT
$562M
$22.8M 5.92%
945,382
+644,496
+214% +$19.7M
AMYT
10
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$13.8M 3.59%
1,140,000
+340,000
+43% +$4.22M
PVLA
11
Palvella Therapeutics
PVLA
$2.27B
$12.2M 3.18%
39,957
-5,987
-13% -$1.31M
HARP
12
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9.88M 2.57%
71,267
-84,153
-54% -$16.1M
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$9.81M 2.55%
142,340
+25,617
+22% +$1.95M
ARGX icon
14
argenx
ARGX
$54.1B
$6.38M 1.66%
21,200
– –
GMAB icon
15
Genmab
GMAB
$19.5B
$4.9M 1.27%
120,000
– –
SPY icon
16
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
– –
-300,000
Closed -$119M
XBI icon
17
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-500,000
Closed -$67.8M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Aquilo Capital Management held 17 positions worth $385M, down 30% from $553M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Aquilo Capital Management withdrew a net $159M in Q2 2021, closing 2 positions and reducing 2 holdings. Its largest reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 58% a quarter earlier.

Against the trend, Aquilo Capital Management added an estimated $19.7M to 4D Molecular Therapeutics.

  • Aquilo Capital Management added most to 4D Molecular Therapeutics in Q2 2021, an estimated $19.7M increase.
  • Aquilo Capital Management's biggest Q2 2021 reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $16.1M.
  • Aquilo Capital Management's ten largest holdings make up 89% of its $385M portfolio in Q2 2021.
  • Aquilo Capital Management opened 0 new positions and closed 2 in Q2 2021.
  • Aquilo Capital Management's portfolio value fell 30% quarter-over-quarter to $385M.

Based on Aquilo Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.